Next-Generation Sequencing and High-Dimensional Phenotyping

The terms next generation sequencing (NGS), massively parallel sequencing (MPS), and deep sequencing are all used to describe a DNA sequencing method that has revolutionised genomic research. A full human genome can be sequenced in a single day using NGS. In comparison, the prior Sanger sequencing technology, which was used to decipher the human genome, took over a decade to complete. Since 2004, next-generation sequencing (NGS) has been available as a new, powerful, high-throughput technology. NGS is the next step in the progression of microarray and sequencing technology. Indeed, NGS can provide information that partially overlaps with data obtained by microarray technique. By explaining immune cell activity and signalling, genomic analysis tools can help progress immunology research. Complex autoimmune diseases (such lupus, rheumatoid arthritis, and multiple sclerosis) and other immunological disorders still have unknown causes. Next-generation sequencing tools, particularly whole exome sequencing, have transformed our understanding of the genetic and molecular basis of hereditary illnesses, resulting in a surge in the finding of new genes linked to primary immunodeficiencies.

Multivariate phenotypic data that use more variables to characterise a phenotype than the number of phenotypes to evaluate are referred to as "high-dimensional" data. If traditional (that is, parametric) statistical approaches are utilised, high-dimensional data create an obstacle to analysis. In general, comparative analysis of high-dimensional data has gotten a lot of attention recently. Simultaneous studies of the peripheral and mucosal immune compartments can reveal information on the pathogenesis of mucosal diseases.

• Immunogenomics
• Immunodeficiencies
• Sequencing
• Age-Emergent Cells